Table 2.
Sp17 expression and its correlation with the clinicopathological characteristics of 50 endometrial cancers
| Clinicopathological characteristics | Negative | Positive | + | ++ | +++ | ++++ |
|---|---|---|---|---|---|---|
| All tumors, n (%) | 17 (34.0) | 33 (66.0) | 9 (18.0) | 7 (14.0) | 13 (26.0) | 4 (8.0) |
| Tumor grade, n (%) | ||||||
| G1 | 4 (8.0) | 13 (26.0) | 4 (8.0) | 1 (2.0) | 6 (12.0) | 2 (4.0) |
| G2 | 11(22.0) | 16 (32.0) | 2 (4.0) | 5 (10.0) | 7 (14.0) | 2 (4.0) |
| G3 | 2 (4.0) | 4 (8.0) | 3 (6.0) | 1 (2.0) | ||
| Histology, n (%) | ||||||
| Adenocancer | 15 (30.0) | 29 (58.0) | 9 (18) | 4 (8.0) | 12 (24.0) | 4 (8.0) |
| Adenosquamous cancer | 2 (4.0) | 4 (8.0) | 3 (6.0) | 1 (2.0) |
-, 5%; +, <25%; ++, 25-50%; +++, 50-75%; ++++ > 75%.